ISU Abxis, Celltrion Bukwang record highest R&D/sales ratio in order

While KOSPI listed pharmaceutical companies had narrowly enlarged R&D expenses in the 1^st half of this year compared to the same period of the last year, KOSDAQ listed pharmaceutical companies stayed the same in the index. In the R&D expense/sales ratio, KOSDAQ listed pharmaceutical companies exceeded 10%, but KOSPI listed pharmas were only close to 10%.

Yakup Shinmoon(www.yakup.com) analyzed ...